Buprenorphine

Major

Buprenorphine Lefamulin Xenleta Increased risk of QT interval prolongation Details Buprenorphine Lemborexant Dayvigo Explained An increased risk of CNS depression and potential next-day somnolence Details Buprenorphine Lenacapavir Sunlenca Explained Increased or reduced buprenorphine exposure Details Buprenorphine Lenvatinib Lenvima Increased risk of QT-interval prolongation Details Buprenorphine Lesinurad Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Letermovir Prevymis Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Leuprolide Eligard Explained An increased risk of QT interval prolongation Details Buprenorphine Levocetirizine Xyzal Explained Increased risk of CNS depression Details Buprenorphine Levodopa Inbrija Explained An increased risk of CNS depression Details Buprenorphine Levofloxacin Levaquin An increased risk of QT interval prolongation Details Buprenorphine Levomilnacipran Explained An increased risk of serotonin syndrome Details Buprenorphine Levorphanol Xyvona Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome Details Buprenorphine Linezolid Zyvox Explained An increased risk of serotonin syndrome or opioid-related toxicity Details Buprenorphine Lisdexamfetamine Arynta Explained An increased risk of serotonin syndrome Details Buprenorphine Lithium Explained Increased risk of serotonin syndrome Details Buprenorphine Lofepramine Explained An increased risk of serotonin syndrome Details Buprenorphine Lofexidine Explained Increased risk of CNS depressant effects and increased risk of QT interval prolongation Details Buprenorphine Lomitapide Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Lonafarnib Zokinvy Explained Increased buprenorphine exposure, an increased risk of buprenorphine-related adverse events and an increased risk of QT interval p... Details Buprenorphine Loperamide Diamode An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Buprenorphine Loprazolam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Lorazepam Ativan Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Lorcaserin Explained An increased risk of serotonin syndrome Details Buprenorphine Lorlatinib Lorbrena Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Lormetazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Loxapine Adasuve Explained An increased risk of respiratory and CNS depression and an increased risk of paralytic ileus Details Buprenorphine Lumacaftor Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Lumefantrine Explained An increased risk of QT interval prolongation Details Buprenorphine Lurasidone Latuda Increased risk of respiratory and CNS depression Details Buprenorphine Macimorelin Explained Increased risk of QT interval prolongation Details Buprenorphine Magnesium Oxybate Xywav Explained An increased risk of CNS depression and clinically significant respiratory depression, obtundation, hypotension, profound sedation... Details Buprenorphine Mavorixafor Xolremdi Explained An increased risk of QT interval prolongation and torsade de pointes Details Buprenorphine Meclizine Antivert Explained An increased risk of respiratory and CNS depression and an increased risk of paralytic ileus Details Buprenorphine Medazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Mefloquine Lariam® An increased risk of QT interval prolongation Details Buprenorphine Melitracen Explained An increased risk of serotonin syndrome Details Buprenorphine Melperone Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Mepenzolate Explained An increased risk of paralytic ileus Details Buprenorphine Meperidine Demerol Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome Details Buprenorphine Mephobarbital Explained An increased risk of respiratory depression and CNS depression Details